GlassScriptPhysician profile
Wesley R Brown
NPI 1932229416
$469.56
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $470.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $109.45 | 2019 | |
| Galderma Laboratories, L.P. | $65.23 | 2019 | |
| Celgene Corporation | $53.73 | 2019 | |
| Pfizer INC. | $45.77 | 2019 | |
| Janssen Biotech, INC. | $35.11 | 2019 | |
| Novartis Pharmaceuticals Corporation | $34.72 | 2019 | |
| Lilly USA, LLC | $28.65 | 2019 | |
| Genzyme Corporation | $27.30 | 2019 | |
| Sun Pharmaceutical Industries INC. | $19.96 | 2019 | |
| Biofrontera INC. | $19.73 | 2019 | |
| Epi Health, LLC | $17.89 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $12.02 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.